Market Overview:
The global migraine drugs market size reached US$ 3.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2027, exhibiting a growth rate (CAGR) of 5.72% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Migraine is a neurological condition that causes unilateral or throbbing pain in the forehead, side of the head or around the eyes. The pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia and phonophobia. Migraine is generally diagnosed by examining the patient’s medical history and symptoms, as well as by performing blood tests, and magnetic resonance imaging (MRI) and computerized tomography (CT) scans. At present, over the counter (OTC) medicines and prescribed injections are available to relieve the symptoms and reduce the frequency and severity of migraine attacks. These drugs are either taken regularly or during attacks or exacerbations of chronic pain.
A significant rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Apart from this, the improvement in reimbursement policies for migraine medications, along with the escalating demand for precision medicines, is also contributing to the market growth. Furthermore, the growing demand for electrical nerve stimulating devices to treat migraine and the expected approval of new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also driving the market growth. However, a decline in clinical visits and procedural treatment of migraines due to social distancing norms has impacted the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global migraine drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on treatment type, drug type, route of administration and distribution channel.
Breakup by Treatment Type:
- Abortive Treatment
- Preventive Treatment
Breakup by Drug Type:
- Triptans
- Ergot Alkaloids
- NSAIDs
- Acetylcholine Inhibitors/ Neurotoxins
- Ditans
- CGRP mAbs
- Others
Breakup by Route of Administration:
Breakup by Distribution Channel:
- Hospital-Based Pharmacies
- Retail Pharmacies
- Others
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Treatment Type, Drug Type, Route of Administration, Distribution Channel, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global migraine drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global migraine drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global migraine drugs market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Migraine Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Treatment Type
6.1 Abortive Treatment
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Preventive Treatment
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Drug Type
7.1 Triptans
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Ergot Alkaloids
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 NSAIDs
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Acetylcholine Inhibitors/ Neurotoxins
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Ditans
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 CGRP mAbs
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Oral
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Injectable
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital-Based Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Abbott Laboratories
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Allergan Plc (Abbvie Inc.)
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 SWOT Analysis
15.3.3 Amgen Inc.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 SWOT Analysis
15.3.4 AstraZeneca Plc
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Eisai Co. Ltd.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Eli Lilly and Company
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Endo International Plc
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 GlaxoSmithKline Plc
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Johnson & Johnson
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Merck & Co.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Novartis AG
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
15.3.13 Pfizer Inc.
15.3.13.1 Company Overview
15.3.13.2 Product Portfolio
15.3.13.3 Financials
15.3.13.4 SWOT Analysis
15.3.14 Sanofi SA
15.3.14.1 Company Overview
15.3.14.2 Product Portfolio
15.3.14.3 Financials
15.3.14.4 SWOT Analysis
15.3.15 Teva Pharmaceutical Industries Limited
15.3.15.1 Company Overview
15.3.15.2 Product Portfolio
15.3.15.3 Financials
15.3.15.4 SWOT Analysis
List of Figures
Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2021
Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2021
Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2021
Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2021
Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: North America: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: United States: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: China: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: India: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Others: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: France: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Others: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 83: Others: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
Figure 89: Global: Migraine Drugs Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million US$), 2022-2027
Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2022-2027
Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2022-2027
Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Migraine Drugs Market Structure
Table 8: Global: Migraine Drugs Market: Key Players